Last viewed:
RVNC
Prices are updated after-hours
RVNC
|
$3.57
-2.46%
-2.52%
1.8M
|
Health Technology
(0.0% 1d)
(-24.0% 1m)
(-88.7% 1y)
(0.0% 2d)
(-2.5% 3d)
(-5.6% 7d)
(12.61%
volume)
Earnings Calendar: 2024-02-27
Market Cap: $ 372,049,742
http://www.revance.com
Sec
Filling
|
Patents
| 193 employees
(United States) Revance Therapeutics, Inc. is a clinical stage biotechnology company. It engages in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company was founded by Jacob M. Waugh and L. Daniel Browne on August 10, 1999 and is headquartered in Newark, CA.
aesthetic
add to watch list
Paper trade
email alert is off
Press-releases
Revance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual Meeting
Published: 2024-04-12
(Crawled : 13:00)
- biospace.com/
VTRS
|
News
A
|
$11.55
1.67%
1.65%
7.2M
|
Health Technology
| -0.17%
| O: -0.17%
H: 0.17%
C: -1.9%
RVNC
|
$3.57
-2.46%
-2.52%
1.8M
|
Health Technology
| -20.31%
| O: -2.01%
H: 1.37%
C: -5.92%
daxxify
neurology
meeting
Revance Announces Pricing of $100.0 Million Public Offering of Common Stock
Published: 2024-03-04
(Crawled : 17:00)
- biospace.com/
VTRS
|
News
A
|
$11.55
1.67%
1.65%
7.2M
|
Health Technology
| -8.26%
| O: 0.0%
H: 0.08%
C: -1.83%
RVNC
|
$3.57
-2.46%
-2.52%
1.8M
|
Health Technology
| -48.85%
| O: -11.6%
H: 3.89%
C: -1.62%
million
offering
Revance to Release Fourth Quarter and Full Year 2023 Financial Results on Wednesday February 28, 2024
Published: 2024-02-21
(Crawled : 15:30)
- biospace.com/
VTRS
|
News
A
|
$11.55
1.67%
1.65%
7.2M
|
Health Technology
| -12.76%
| O: -0.15%
H: 0.76%
C: 0.3%
RVNC
|
$3.57
-2.46%
-2.52%
1.8M
|
Health Technology
| -35.21%
| O: 0.18%
H: 0.72%
C: -2.72%
year
financial
results
Global Cell Penetrating Peptide Market Forecast Report to 2030, Featuring Biosynth, Creative Peptides, Cupid Peptide, Alta Bioscience, AnaSpec, Peptomyc, PolyPeptide, Bachem & Sarepta Therapeutics
Published: 2024-02-05
(Crawled : 11:00)
- prnewswire.com
SRPT
|
$124.27
6.11%
5.75%
1.3M
|
Health Technology
| 2.46%
| O: 0.12%
H: 3.45%
C: 3.4%
RVNC
|
$3.57
-2.46%
-2.52%
1.8M
|
Health Technology
| -33.52%
| O: -2.42%
H: 1.05%
C: -2.67%
report
cell
global
therapeutics
market
Revance to Participate in the Guggenheim 6th Annual Biotechnology Conference
Published: 2024-02-01
(Crawled : 21:00)
- biospace.com/
VTRS
|
News
A
|
$11.55
1.67%
1.65%
7.2M
|
Health Technology
| -1.87%
| O: -0.42%
H: 1.75%
C: 1.28%
RVNC
|
$3.57
-2.46%
-2.52%
1.8M
|
Health Technology
| -29.03%
| O: 1.59%
H: 4.11%
C: 0.78%
conference
Revance Provides Corporate Update, Preliminary Fourth Quarter and Full Year 2023 Financial Results, and Financial Outlook
Published: 2024-01-08
(Crawled : 14:00)
- biospace.com/
VTRS
|
News
A
|
$11.55
1.67%
1.65%
7.2M
|
Health Technology
| -3.59%
| O: -0.83%
H: 0.72%
C: -1.43%
RVNC
|
$3.57
-2.46%
-2.52%
1.8M
|
Health Technology
| -57.25%
| O: -13.17%
H: 3.45%
C: -2.76%
year
financial
Revance to Release Third Quarter 2023 Financial Results on Wednesday, November 8, 2023
Published: 2023-11-01
(Crawled : 13:00)
- biospace.com/
VTRS
|
News
A
|
$11.55
1.67%
1.65%
7.2M
|
Health Technology
| 29.78%
| O: -0.45%
H: 0.96%
C: 0.68%
RVNC
|
$3.57
-2.46%
-2.52%
1.8M
|
Health Technology
| -54.75%
| O: -0.63%
H: 1.66%
C: 1.15%
financial
results
Global Facial Injectable Market Analysis Report 2023-2028: New Product Launches, Increased Male Aesthetics, and Emerging Markets Driving Growth
Published: 2023-09-06
(Crawled : 10:00)
- prnewswire.com
ABBV
|
News
|
$167.8
-1.03%
-0.06%
4.1M
|
Health Technology
| 14.85%
| O: -0.1%
H: 0.0%
C: 0.0%
RVNC
|
$3.57
-2.46%
-2.52%
1.8M
|
Health Technology
| -79.59%
| O: -0.46%
H: 1.38%
C: -2.87%
EOLS
|
$11.48
-1.88%
-1.92%
260K
|
Health Technology
| 18.19%
| O: 0.41%
H: 0.92%
C: -0.1%
report
global
growth
market
Revance to Host Investor Day on September 19, 2023
Published: 2023-08-22
(Crawled : 14:00)
- biospace.com/
VTRS
|
News
A
|
$11.55
1.67%
1.65%
7.2M
|
Health Technology
| 2.67%
| O: -0.18%
H: 0.45%
C: -0.62%
RVNC
|
$3.57
-2.46%
-2.52%
1.8M
|
Health Technology
| -79.66%
| O: 0.28%
H: 2.33%
C: 1.65%
day
U.S. FDA Approves First Therapeutic Indication for Revance’s DAXXIFY® (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia
Published: 2023-08-14
(Crawled : 13:00)
- biospace.com/
VTRS
|
News
A
|
$11.55
1.67%
1.65%
7.2M
|
Health Technology
| 1.76%
| O: -0.35%
H: 0.0%
C: -1.06%
RVNC
|
$3.57
-2.46%
-2.52%
1.8M
|
Health Technology
| -81.12%
| O: 6.13%
H: 1.54%
C: -3.04%
daxxify
fda
treatment
injection
See all
Last 15 days Sec forms
File Id
Form
Published Date
Transaction Date
Direction
Code
Amount Transacted
Owned Amount
0001479290-24-000068
4
2024-03-19
2024-03-18
Sell
S
9211
167550
0001479290-24-000068
4
2024-03-19
2024-03-15
Sell
F
2967
176761
0001479290-24-000067
4
2024-03-19
2024-03-18
Sell
S
8125
137815
0001479290-24-000067
4
2024-03-19
2024-03-15
Sell
F
3269
145940
0001479290-24-000066
4
2024-03-19
2024-03-18
Sell
S
9361
192666
0001479290-24-000066
4
2024-03-19
2024-03-15
Sell
F
3822
202027
0001479290-24-000065
4
2024-03-19
2024-03-15
Sell
F
17228
994935
0001479290-24-000065
4
2024-03-19
2024-03-15
Sell
F
3305
1012163